Drug Profile


Alternative Names: BIIB 067; ISIS 333611; ISIS-SOD1Rx; SODr/h333611

Latest Information Update: 15 Jun 2016

Price : $50

At a glance

  • Originator Center for Neurologic Study; Isis Pharmaceuticals; Ludwig Institute for Cancer Research
  • Developer Ionis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Superoxide dismutase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis

Most Recent Events

  • 07 Mar 2017 Biogen plans a phase I trial for Amyotrophic lateral sclerosis (NCT03070119)
  • 15 Jun 2016 Phase-II clinical trials in Amyotrophic lateral sclerosis in Belgium, Canada, USA (Intrathecal) (Ionis Pharmaceuticals pipeline, June 2016)
  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top